ANAVEX outlines corporate milestones, drug advancement plans for 2008
- Details
- Category: Business
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) reported that the company achieved significant development of its lead drug candidates and in the growth of its management and scientific teams during 2007. The company further disclosed key corporate objectives for 2008.
Roche invests 430 million Swiss francs at sites in Germany and Switzerland
- Details
- Category: Roche
Roche has approved extensive investment plans for its Penzberg, Mannheim and Kaiseraugst sites. Around 280 million Swiss francs will be invested in expanding biotech drug research and development activities at Penzberg. This decision will ensure that the company's own value added chain is exploited to its full potential in the development and production of biopharmaceuticals mainly for oncology applications.
Novartis achieves record results in 2007 underscoring benefits of strategic healthcare portfolio
- Details
- Category: Novartis
Novartis achieved record results for the total Group in 2007, with net sales rising 8% (+3% in local currencies) and net income advancing 66% to USD 12.0 billion. Sandoz and Vaccines and Diagnostics led the expansion with double-digit net sales growth and strong contributions to operating income, while Consumer Health provided additional support with a solid performance.
Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor
- Details
- Category: Pfizer
Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scilâs cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP.
First Head to Head Study Comparing CRESTOR and LIPITOR®
- Details
- Category: AstraZeneca
AstraZeneca announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis in high risk patients.
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R)
- Details
- Category: Product
Pharmion Corporation (Nasdaq: PHRM) announced the submission of a MAA with the European Medicines Agency (EMEA) for Vidaza(R) (azacitidine for injection) in the treatment of patients with higher-risk MDS in the European Union (EU).
Pfizer Wins Key New York State Court Ruling on Celebrex
- Details
- Category: Pfizer
Pfizer Inc announced that a New York state court ruled in favor of the company on an important motion relating to litigation over Pfizer's Celebrex medication. New York Supreme Court Justice Shirley W. Kornreich ruled that the plaintiffs suing Pfizer in New York failed to present reliable scientific evidence necessary to prove that Celebrex can cause heart attacks and strokes at 200 mg daily - the most commonly prescribed dosage of the Pfizer pain medication.
More Pharma News ...
- Roche engages in four additional AIDS Technology Transfers
- Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
- Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
- Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate
- Expanded Labeling for MabCampath® in Europe
- New pharmaceutical candidate Lu AA37096 enters Lundbeck's development pipeline
- Pfizer Completes Sale of Consumer Healthcare Business